Pervilleine F, a New Tropane Alkaloid Aromatic Ester that Reverses Multidrug Resistance

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3607-3615

  Mi, Qiuwen ^a   Cui, Baoliang ^a,b   Lantvit, Daniel ^a   Reyes Lim, Eulenia ^a   Chai, Heebyung ^a   Pezzuto, John M ^a,c   Kinghorn, A Douglas ^a   Swanson, Steven M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Pure World Botanicals   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Cancer chemotherapy; Cell cycle; Cross resistance; Flow cytometry; G2 M arrest; Hollow fiber test; MDR1 gene; MTT; Multidrug resistance; P glycoprotein; Pervilleine F; Verapamil

Indexed keywords

ANTINEOPLASTIC AGENT; BACCATIN III; CHLOROFORM; DACTINOMYCIN; DAUNORUBICIN; ELLIPTICINE; ESTER DERIVATIVE; MITHRAMYCIN; PACLITAXEL; PERVILLEINE F; PLANT EXTRACT; PODOPHYLLOTOXIN; TROPANE ALKALOID; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; DRUG SENSITIVITY; FEMALE; FRACTIONATION; HUMAN; HUMAN CELL; IC 50; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; ESTERS; FLOW CYTOMETRY; HUMANS; MOUTH NEOPLASMS; TROPANES; VERAPAMIL; VINBLASTINE;

EID: 0344874160     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Vire WVD, Marquet RL, Stoter G, Bruijn EAD and Eggermont AMM: In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci 35: 1-57, 1998.
2. Kawase M and Motohashi N: New multidrug resistance reversal agents. Curr Drug Targets 4: 31-43, 2003.
3. Mi Q, Cui B, Silva GL, Lanwit D, Lim E, Chai H, Hollingshead MG, Mayo JG, Kinghorn A D and Pezzuto JM: Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay. Cancer Lett 184: 13-20, 2002.
4. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE and Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs 14: 175-181, 2003.
5. Kohler S and Stein WD: Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles. Biotechnol Bioeng 81: 507-517, 2003.
6. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH, Pyo S and Rhee DK: Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 65: 75-82, 2003.
7. Che XF, Nakajima Y, Sumizawa T, Ikeda R, Ren XQ, Zheng CL, Mukai M, Furukawa T, Haraguchi M, Gao H, Sugimoto Y and Akiyama S: Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett 187: 111-119, 2002.
8. Bates SF, Chen C, Robey R, Kang M, Figg WD and Fojo T: Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 243: 83-96, 2002.
9. Stein WD: Reversers of the multidrug resistance transporter P-glycoprotein. Curr Opin Investig Drugs 3: 812-817, 2002.
10. Hyafil F, Vergely C, Vignaud PD and Grand-Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-4602, 1993.
11. Kinghorn AD, Farnsworth, NR, Soejarto DD, Cordell GA, Pezzuto JM, Udeani GO, Wani MC, Wall ME, Navarro HA, Kramer RA, Menendez AT, Fairchild CR, Lane KE, Forenza S, Vyas DM, Lam KS and Shu YZ: Novel strategies for the discovery of plant-derived anticancer agents. Pure Appl Chem 71: 1611-1618, 1999.
12. Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD and Pezzuto JM: Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 61: 4030-4037, 2001.
13. Silva GL, Cui B, Chuvez D, You M, Chai H, Rasoanaivo P, Lynn SM, O'Neill MJ, Lewis JA, Besterman JM, Monks A, Farnsworth NR, Cordell GA, Pezzuto JM and Kinghorn AD: Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei. J Nat Prod 64: 1514-1520, 2001.
14. Chavez D, Cui B, Chai H, Garcia R, Mejia M, Farnsworth NR, Cordell GA, Pezzuto JM and Kinghorn AD: Reversal of multidrug resistance by tropane alkaloids from the stems of Erythroxylum rotundifolium. J Nat Prod 65: 606-610, 2002.
15. Mi Q, Cui B, Chuvez D, Chai H, Cordell GA, Hedayat S, Zhu H, Kinghorn AD and Pezzuto JM: Characterization of novel tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype. Anticancer Res 22: 1385-1398, 2002.
16. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
17. Casciari JJ, Hollingshead MG, Alley MC, Mayo JG, Malspeis L, Miyauchi S, Grever MR and Weinstein JN: Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst 86: 1846-1852, 1994.
18. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L and Grever MR: In vivo cultivation of tumor cells in hollow fibers. Life Sci 57: 131-141, 1995.
19. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM and Kerr JS: The hollow fiber assay: continued characterization with novel approaches. Anticancer Res 20: 903-911, 2000.
20. Mi Q, Lantvit D, Reyes-Lim E, Chai H, Zhao W, Lee IS, Peraza-Sanchez S, Ngassapa O, Kardono LBS, Riswan S, Hollingshead MG, Mayo JG, Kinghorn AD, Cordell GA and Pezzuto JM: Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests. J Nat Prod 65: 842-850, 2002.
21. Waller DP, Zaneveld LJD and Fong HHS: In vitro spermicidal activity of gossypol. Contraception 22: 183-187, 1980.
22. Watanabe T, Tsuge H, Oh-Hara T, Naito M, and Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235-241, 1995.
23. Klopman G, Shi LM and Ramu A: Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52: 323-334, 1997.
24. Zamora JM, Pearce HL and Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462, 1988.
25. Devine SE and Melera PW: Diversity of multidrug resistance in mammalian cells. J Biol Chem 269: 6133-6139, 1994.
26. Devine SE, Ling V and Melera PW: Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 89: 4564-4568, 1992.
27. Andreu JM and Barasoain I: The interaction of baccatin III with the taxol binding site of microtubules determined by a homogeneous assay with fluorescent taxoid. Biochemistry 40: 11975-11984, 2001.
28. Choi CH and Ling V: Isolation and characterization of daunorubicin-resistant AML-2 sublines. Mol Cells 7: 170-177, 1997.
29. Chevallier-Multon MC, Jacquemin-Sablon A, Besselievre R, Husson HP and Le Pecq JB: Comparative cytotoxicities of a series of ellipticine and olivacine derivatives on multidrug resistant cells of human and murine origins. Anticancer Drug Des 5: 319-335, 1990.
30. Whelan RD and Hill BT: Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation. Breast Cancer Res Treat 26: 23-39, 1993.
31. Barret JM, Salles B, Provot C and Hill BT: Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis 18: 2441-2445, 1997.
32. Etievant C, Schambel P, Guminski Y, Barret JM, Imbert T and Hill BT: Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series. Anticancer Drug Des 13: 317-336, 1998.
33. Geney R, Ungureanu M, Li D and Ojima I: Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med 40: 918-925, 2002.
34. Choi CH, Sun KH, An CS, Yoo JC, Hahm KS, Lee IH, Sohng JK and Kim YC: Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3′ ,4′-pentamethoxyflavone (sinensetin). Biochem Biophys Res Commun 295: 832-840, 2002.
35. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP and Trent JM: Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res 47: 5455-5460, 1987.
36. Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P and Chen Y: Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 3: 253-263, 2001.
37. Hader C, Hadnagy W and Seemayer NH: A rapid method for detection of nongenotoxic carcinogens of environmental pollutants using synchronized V79 cells and flow cytometry. Toxicol Lett 88: 99-108, 1996.
38. Wagner MM, Paul DC, Shih C, Jordan MA, Wilson L and Williams DC: In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol 43: 115-125, 1999.
39. 1 phase of growth factor-induced endothelial cell proliferation by various calcium channel blockers. Cancer Detect Prev 21: 332-339, 1997.
40. Phillipes RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ and Double JA: Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs. Cancer Res 58: 5263-5266, 1998.